Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
P&G, with roughly $68 billion in annual revenue, said it has invested millions in creating and testing refills for detergents over the years and is now trying to push in to mainstream beauty and body care refills – which are virtually  unheard of. It recently began offering some Olay face-cream jars with refill pouches on Olay.com, telling Reuters it has plans to expand the sales of the pouches in Europe early next year. “We’re learning on our legs so I don’t know that we’re in a position to say, ‘Hey, here’s the magic to selling refills,’” P&G spokesman Damon Jones said. Beauty products retailer The Body Shop, owned by Brazil’s Natura Cosmeticos SA NATU3.SA, says it plans to roll out “refill stations” in its stores globally next year, allowing shoppers to buy reusable metal containers to fill with Body Shop shower gels or creams. The company had offered refills at its stores in the early 1990s, but discontinued them in 2003, citing a lack of consumer demand. Unilever, which has set targets for reducing and recycling plastic by 2025, in October announced the planned launch of “refill sticks” of deodorants under its Dove line of personal care products on Loopstore.com. The website, operated by recycling company TerraCycle, offers consumers the chance to buy some household products in ultra-durable packaging with refills delivered to their doors, milkman-style. Across the consumer goods industry, results for refillable products have been mixed so far as many shoppers are far too set in their ways to be easily weaned from living in a throwaway culture. While refills are less expensive to purchase - generally priced at 20% to 30% less per item than the containers they are aimed to replenish, according to Unilever - shoppers have so far, for the most part, failed to snap them up, the companies said. SC Johnson & Son Inc, marketer of Windex and Pledge, said refills and concentrates so far have not played well with either Americans or Europeans over the decade they have been offered, with unit sales of such products pretty much flat. It pulled concentrated refills for Shout stain remover off the shelves because they were not selling very well. In 2010, Unilever put 20-liter tanks to dispense detergents in Walmart Inc’s (WMT.N) British supermarket chain Asda, and provided flexible pouches for customers to refill. But with leaky machines, safety and maintenance problems and the high costs of upkeep, Unilever said the tests fell short of expectations. Asda was also unhappy because the tanks occupied a lot of space. “None of them sell very well – it is a convenience issue,” SC Johnson CEO Fisk Johnson told Reuters. Johnson said some people find it painstaking to wash and refill bottles themselves while others worry that smaller bottles filled with concentrates are less “bang-for-your-buck” than the larger ones they have used for years. Still, the privately held company said it was expanding its refill offerings this year to address concerns surrounding plastic waste and is also testing refill stations for cleaning products with UK retailer Waitrose, owned by Britain’s John Lewis [JLPLC.UL]. The Waitrose tests are showing the first signs of progress in refill sales, Johnson said, and the company is now thinking of expanding the project. Even if consumers are comfortable using refills for some household goods, it is more complicated to sell them for products like Pantene shampoo and Olay creams, P&G spokesman Jones said. For instance, with beauty products, the look and feel of packaging is a big factor in creating and maintaining customer loyalty, while delivering an environmental benefit, he said. Some shoppers say they want to buy refillable products, but that the offerings are not available at many stores. Earlier this year, dozens of consumers took to social media to urge The Body Shop to bring back its refill counters. “Refill, refill, refill!” Twitter user @JaiChipperfield said on July 22, joining a thread in which several other shoppers demanded the return of refills. “Seems to me that judging by these comments your customers want to see the return of refills,” @JaiChipperfield added. “Me too, it would be brilliant to see that return.”  The Body Shop eventually responded to those pleas. “Now with the renewed focus on sustainability, we believe it is the right time to return with it,” Body Shop spokeswoman Lucy Muircroft told Reuters this week.

Ex Output:
Procter & Gamble, rivals take refills into beauty aisle.


Ex Input:
Biotechnology company Alkermes said earlier in the day that  it expected Lilly to drop out of their program to develop an  inhaled insulin treatment for diabetes, sending Alkermes shares  down more than 9 percent. Lilly’s decision marks the third setback in recent months  for inhaled insulin formulations, once deemed potential  blockbuster products because of their greater convenience than  standard injectable insulin. Cambridge, Massachusetts-based Alkermes, which makes the  alcohol addiction drug Vivitrol, said Lilly has the right to  terminate its license to the inhaled treatment, Air Insulin, at  its discretion. “While Lilly may elect not to commercialize Air Insulin,  Alkermes believes that the phase 3 safety and efficacy trials  should be completed,” Alkermes said in a statement. After Lilly’s announcement, the company said it was  evaluating the impact of the termination, which will become  effective in 90 days. Indianapolis-based Lilly said its decision was not due to  safety concerns, “but rather was a result of increasing  uncertainties in the regulatory environment, and a thorough  evaluation of the evolving commercial and clinical potential of  the product compared to existing medical therapies.”    Lilly Chief Operating Officer John Lechleiter said in a  statement that the company is beginning the process of halting  ongoing clinical studies. Lilly said it will record a first-quarter 2008 charge of  around $90 million to $120 million, or 5 cents to 7 cents per  share. The company said its adjusted earnings per share outlook  remains unchanged at $3.85 to $4.00, while net earnings will  range from $3.73 to $3.90. Lilly’s action comes just five months after Pfizer Inc  abandoned Exubera, the first approved inhaled form of insulin,  and returned rights to the product to longtime partner Nektar  Therapeutics. Exubera had dismal sales because patients were turned off  by the clumsy device used to administer the powdered insulin  and because doctors were concerned by the drug’s tendency to  slightly impair lung function. Alkermes Chairman Richard Pops, in an interview with  Reuters in October, said Air Insulin may have similar effects  on lung function. “We’re assuming that pulmonary insulins in that regard are  all pretty much the same,” he said, although a conclusive  picture of Air Insulin’s safety will not emerge until two-year  safety trials of the product end later this year. A second setback for inhaled insulin came in January, when  Novo Nordisk said it was halting development of its AERx  product, meant to deliver inhaled droplets. The Danish  drugmaker said AERx did not have adequate sales potential,  given the limited commercial success seen with Exubera. Morgan Stanley analyst Jami Rubin said on Friday Lilly’s  abandonment of AIR Insulin made good business sense. “We are not (at) all surprised, and have never been strong  advocates of the pulmonary insulin agents, following the poor  launch and ultimate demise of Pfizer and Nektar’s Exubera and  Novo Nordisk’s termination of its AERx program,” Rubin said in  a research note. Rubin said Alkermes, known for its drug-delivery  technology, is unlikely to continue development of Air Insulin  without Lilly, “given that this represents the third  termination of a pulmonary insulin drug.”    But she said the sharp drop in Alkermes shares represented  a buying opportunity for investors because Air Insulin had only  paltry sales potential. She said investors should be focused instead on another  product Alkermes is developing with Lilly: a long-acting  formulation of Lilly’s Byetta diabetes treatment called Byetta    “We estimate that Byetta LAR could be worth $11 to $12 for  the (Alkermes) stock,” Ryan said. Alkermes shares fell $1.14 to close at $11.26 on Nasdaq. Lilly, a far larger company with an array of big-selling  products, rose 2 cents to end at $49.70 on the New York Stock  Exchange, and was slightly lower at $49.67 in after-hours  trading.

Ex Output:
Eli Lilly drops inhaled insulin program.


Ex Input:
“Independents need to know they can invest their vote in the Democratic Party,” Carter said Tuesday during his annual report at his post-presidential center and library in Atlanta, where he offered caution about the political consequences should Democrats “move to a very liberal program, like universal health care.” That’s delicate — and, Carter admitted, even contradictory — advice coming from the 93-year-old former president, and it underscores the complicated political calculations for Democrats as they prepare for the November midterms and look ahead to the 2020 presidential election. “Rosie and I voted for Bernie Sanders in the past,” Carter noted. He was referring to his wife, Rosalynn, and their support for the Vermont senator, an independent who identifies as a democratic socialist, over establishment favorite Hillary Clinton in the 2016 Democratic presidential primary. At another point, he pointed to California’s environmental policies — limits on carbon emissions, stiffer fuel-efficiency standards — as the model for combating climate change. Still, Carter stressed, Democrats nationally must “appeal to independents” who are souring on the current administration. Trump’s job approval rating, according to Gallup, has dipped to 40 percent, mostly because of declining support among independents. Carter alluded to arguments from self-identified progressives that Democrats will sacrifice votes on the left if they don’t embrace the liberal base: “I don’t think any Democrat is going to vote against a Democratic nominee,” and he insisted that he’s not asking the left to sacrifice its goals, only to see that winning elections is necessary to accomplish any of them. There is some historical irony in Carter’s analysis. He came to the White House in 1976 from the moderate wing of the Democratic Party, and he clashed with party liberals, drawing a spirited primary challenge in 1980 from Massachusetts Sen. Ted Kennedy. Carter prevailed, but he was wounded, abandoned by Kennedy’s most liberal supporters and unable to win over independents who helped deliver a landslide for Republican Ronald Reagan. Carter’s latest handicapping comes near the conclusion of a midterm primary season that has seen Democratic primary voters move the party to the left. In some states and districts, that means nominating full-throated advocates of single-payer health care, a $15 minimum wage and abolishing or at least overhauling the federal Immigration and Customs Enforcement agency. In other races, it means nominees who back more cautious moves to the left, such as background checks before certain gun purchases, a “public option” health insurance plan to compete alongside private insurance policies, step raises for the minimum wage and an immigration overhaul that offers legal status to some immigrants in the country illegally. Carter did not delve into those distinctions, instead offering a sweeping condemnation of his latest successor to remind Democrats of the stakes. He denounced the administration’s latest environmental policy proposal to make it easier for energy companies to release methane gas that contributes to climate change. He singled out Trump’s policy of separating immigrant families at the border, including those seeking asylum. “America is inherently committed to human rights, and I think in the future we will let that prevail,” Carter said, “but for the next two years, I can’t predict the imprisoned children are going to be any better off — unfortunately.” Carter has previously criticized Trump for his repeated falsehoods, and he’s chided Trump for his hardline support for Israel over Palestinians. Yet Carter has found common ground with Trump on other foreign policy fronts, and did so again Tuesday. While avoiding any mention of the special counsel’s investigation into whether Trump’s presidential campaign coordinated with Russia in the 2016 U.S. election, Carter said he has engaged for years with Russian President Vladimir Putin concerning the ongoing Syrian civil war. “I have his email address,” Carter said, adding that he and Putin share the same Russian river as their favorite spot for salmon fishing. That friendship, Carter said, means when Russia and other nations hold multilateral talks about the Syrian conflict, “Quite often they invite the Carter Center. ... They do not invite the U.S. government.” Carter also praised Trump for meeting with North Korean leader Kim Jong Un. Carter repeated his frustrations with the last Democratic president, Barack Obama, for not engaging more directly with the insular Asian nation. Carter said he’s not sure Trump has made real progress yet with North Korea, but he endorsed calls for the U.S. to formally declare an end to the Korean War and normalize relations with Pyongyang. “Let them be part of the community of nations,” he said. “I think that would be enough in itself to bring an end to the nuclear program in North Korea.” ___ Follow Barrow on Twitter at https://twitter.com/BillBarrowAP

Ex Output:

Jimmy Carter: To beat Trump, Dems cannot scare off moderates.